Multiple myeloma is a cancer arising from the plasma cells in the bone marrow.

Worldwide, there are approximately 750,000 people living with myeloma.

Myeloma is the second most common hematologic (blood) cancer in the United States. Myeloma accounts for 1.8% of all cancers diagnosed.

The most common symptoms of myeloma are bone pain, fatigue, and infections.

Myeloma is treatable and outcomes continue to improve.

More information about myeloma is available on the IMF website myeloma.org.

The IMF InfoLine provides immediate help. Call our trained information specialists or email InfoLine@myeloma.org.

Please visit myeloma.org and join us on twitter.com/imfmyeloma and facebook.com/myeloma.

To receive a complimentary subscription to the IMF’s email newsletters, send your request to subscriptions@myeloma.org. Newsletters are available in English, French, German, Italian, or Spanish.
Established in 1990, the International Myeloma Foundation (IMF) is the oldest and largest organization focusing specifically on myeloma. With more than 450,000 members in 140 countries, we serve patients and family members, and the medical community. The IMF provides a wide range of programs in the areas of Research, Education, Support, and Advocacy.

The Black Swan Research Initiative® (BSRI®), the IMF’s signature research project, is a groundbreaking, multinational, and collaborative effort to develop the first definitive cure for myeloma.

The IMF’s International Myeloma Working Group (IMWG) is comprised of more than 220 of the world’s top myeloma experts. The IMWG leads the field in both lab-based and translational/clinical research.

Learn more about the way the IMF is helping to improve the quality of life of myeloma patients while working toward prevention and a cure. Contact us or visit myeloma.org.